DE68925971T2 - Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte - Google Patents

Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte

Info

Publication number
DE68925971T2
DE68925971T2 DE1989625971 DE68925971T DE68925971T2 DE 68925971 T2 DE68925971 T2 DE 68925971T2 DE 1989625971 DE1989625971 DE 1989625971 DE 68925971 T DE68925971 T DE 68925971T DE 68925971 T2 DE68925971 T2 DE 68925971T2
Authority
DE
Germany
Prior art keywords
expression
products
growing medium
cell growth
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE1989625971
Other languages
English (en)
Other versions
DE68925971D1 (de
Inventor
William Howarth
Brian Maiorella
Duane Inlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22939976&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68925971(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of DE68925971D1 publication Critical patent/DE68925971D1/de
Publication of DE68925971T2 publication Critical patent/DE68925971T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
DE1989625971 1988-09-23 1989-09-13 Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte Expired - Fee Related DE68925971T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24863488A 1988-09-23 1988-09-23
PCT/US1989/003986 WO1990003430A1 (en) 1988-09-23 1989-09-13 Cell culture medium for enhanced cell growth, culture longevity and product expression

Publications (2)

Publication Number Publication Date
DE68925971D1 DE68925971D1 (de) 1996-04-18
DE68925971T2 true DE68925971T2 (de) 1996-09-05

Family

ID=22939976

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1989625971 Expired - Fee Related DE68925971T2 (de) 1988-09-23 1989-09-13 Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte

Country Status (6)

Country Link
EP (1) EP0435911B1 (de)
JP (1) JP2783294B2 (de)
AT (1) ATE135397T1 (de)
AU (1) AU632065B2 (de)
DE (1) DE68925971T2 (de)
WO (1) WO1990003430A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10120835A1 (de) * 2001-04-27 2002-11-07 Sifin Inst Fuer Immunpraeparat Verfahren zur Herstellung von monoklonalen Antikörpern

Families Citing this family (547)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621972B2 (en) * 1988-12-14 1992-03-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell culture medium for human liver epithelial cell line
GB9004390D0 (en) * 1990-02-27 1990-04-25 Ici Plc Process
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB2251249B (en) * 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
WO1993013196A2 (en) * 1991-12-24 1993-07-08 Genzyme Corporation Method for increasing recombinant protein production
DE10199044I2 (de) 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
US5631159A (en) * 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
EP2221361A3 (de) 1996-08-30 2011-02-09 Life Technologies Corporation Methode zur Herstellung eines Polypeptids in vitro in einer Säugerzelle in einem Kulturmedium ohne Serum und ohne Proteine
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6309864B1 (en) * 1997-04-03 2001-10-30 Yoshitomi Pharmaceutical Industries, Ltd. Process for producing foreign proteins
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999010372A1 (en) 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
EP1953229A3 (de) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatische Brust- und Dickdarmkrebs-regulierte Gene
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
ATE519840T1 (de) 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
EP1171615B1 (de) 1999-04-26 2006-12-13 Genentech, Inc. Zellenzuchtverfahren für glycoproteine
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団／蛍光体、およびそれらの使用法
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
JP2003513623A (ja) * 1999-10-29 2003-04-15 カイロン コーポレイション 細胞培養物においてウイルスベクター力価を改善するための方法および細胞死を減少するための方法
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
EP1757311B1 (de) 1999-12-24 2009-02-11 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
AU2001229367A1 (en) 2000-01-10 2001-07-24 Chiron Corporation Genes differentially expressed in breast cancer
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1303293B1 (de) 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2454731C (en) 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
NZ543755A (en) 2001-08-29 2008-04-30 Genentech Inc Bv8 nucleic acids and polypeptides with mitogenic activity
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
AU2002357322A1 (en) 2001-12-19 2003-07-09 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
KR20080106369A (ko) 2002-01-02 2008-12-04 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP1553912A4 (de) 2002-06-07 2007-08-08 Genentech Inc Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc protein purification
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1615659B1 (de) 2003-03-12 2014-04-16 Genentech, Inc. Verwendung von bv8 und/oder eg-vegf zur förderung der hematopoiese
ME00425B (me) 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
NZ596981A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
WO2005076938A2 (en) 2004-02-11 2005-08-25 Massachusetts Institute Of Technology Multi-polymer-coated magnetic nanoclusters
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
EP1732944B1 (de) 2004-04-07 2012-09-05 The University of Chicago Monomere, rotfluoreszierende proteine
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20060069019A1 (en) 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
BRPI0513534A (pt) 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
SI3530673T1 (sl) 2004-09-03 2022-08-31 Genentech, Inc. Humanizirani antagonisti proti beta7 in njihove uporabe
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
EP1835022B1 (de) 2005-01-05 2015-02-11 Chugai Seiyaku Kabushiki Kaisha Zellkulturverfahren und dessen nutzung
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
MX2007011617A (es) 2005-03-21 2008-03-13 Applera Corp Compuestos de alfa-cetoamida como inhibidores de la cisteina proteasa.
CN101495645B (zh) 2005-03-23 2012-08-22 生物-拉德实验室公司 蛋白纯化方法
ES2772674T3 (es) 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
EP1919931A4 (de) 2005-08-31 2010-01-20 Univ California Zelluläre peptidsequenzbibliotheken (clips) und verwendungsverfahren dafür
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CA2629715C (en) 2005-11-18 2016-05-03 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
ES2388932T3 (es) 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
ES2535856T3 (es) 2005-12-15 2015-05-18 Genentech, Inc. Métodos y composiciones para dirigirse a la poliubiquitina
ES2526204T3 (es) 2006-01-05 2015-01-08 Genentech, Inc. Anticuerpos anti-EphB4 y métodos para usar los mismos
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2389948A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP3420817A1 (de) 2006-06-12 2019-01-02 The Jackson Laboratory Kryoschutzmedien für spermien
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
ME00588A (en) 2006-08-18 2011-12-20 Prlr-specific antibody and uses thereof
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
KR101581279B1 (ko) 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
EP2061814B1 (de) 2006-10-27 2012-06-06 Genentech, Inc. Antikörper und immunkonjugate sowie ihre verwendungen
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
CA2673851C (en) 2007-01-22 2016-05-03 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
DK2115126T3 (en) * 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
WO2008136398A1 (ja) * 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
DK2164992T3 (en) 2007-05-30 2016-08-15 Lpath Inc COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CN101809034B (zh) 2007-06-07 2015-07-08 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
SI2207790T1 (sl) 2007-09-05 2013-11-29 Genentech, Inc. Biološko aktivni C-terminalni arginin vsebujoči peptidi
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
PT2215117E (pt) 2007-10-30 2015-04-01 Genentech Inc Purificação de anticorpo por cromatografia de troca de catiões
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
CN101918444A (zh) 2007-11-08 2010-12-15 健泰科生物技术公司 抗因子b抗体及其用途
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
PT2848625T (pt) 2008-08-14 2019-10-25 Genentech Inc Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena.
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2911256A1 (en) 2008-10-20 2010-12-09 Robert K. Hickman Isolation and purification of antibodies using protein a affinity chromatography
US9101645B2 (en) 2008-10-22 2015-08-11 Genentech, Inc. Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US10080578B2 (en) 2008-12-16 2018-09-25 Nico Corporation Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
US20110250644A1 (en) 2008-12-19 2011-10-13 Schering Corporation Feed supplement for mammalian cell culture and methods of use
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
ES2932874T3 (es) 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
CN102471775A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 通过力传导增加细胞生产
RU2567803C2 (ru) 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
EP3760712A1 (de) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Herstellung von proteinen in glutamin-freien zellkulturmedien
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
EP3736338A1 (de) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Verbesserte proteinreinigung durch eine modifizierte protein-a-elution
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
BR112012009245A2 (pt) 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
MX2012004711A (es) 2009-10-20 2012-05-23 Abbott Lab Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
RU2559533C2 (ru) 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
MX2012004638A (es) 2009-10-22 2012-07-04 Genentech Inc Modulacion de degeneracion de axones.
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
US8524458B2 (en) 2009-11-09 2013-09-03 Abbvie Inc. Secretory protein biomarkers for high efficiency protein expression
CA2780319A1 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
MX2012005864A (es) 2009-11-20 2012-08-31 Amgen Inc Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
CN103724432B (zh) 2009-11-30 2016-06-08 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
EP2538981B1 (de) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
CA3027824A1 (en) 2010-02-23 2011-09-01 Sanofi Anti-alpha2 integrin antibodies and their uses
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011123489A2 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN104777301B (zh) 2010-05-10 2018-04-20 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
KR20130098165A (ko) 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-ｐｅｔ 영상화 및 그의 용도
CA2802057A1 (en) 2010-06-16 2011-12-22 Abbvie Inc. Comparison of protein samples
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
SG187787A1 (en) 2010-08-10 2013-03-28 Amgen Inc Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
AU2011296702A1 (en) * 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
CN105753933A (zh) 2010-09-20 2016-07-13 Abbvie 公司 采用模拟移动床色谱纯化抗体
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
CA2814030C (en) 2010-10-08 2019-04-30 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
KR101687060B1 (ko) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 조절제 및 그의 용도
KR101708533B1 (ko) 2010-10-08 2017-02-20 상하이 켁신 바이오테크 씨오., 엘티디. 재생불량 빈혈과 관련된 모에신 단편
CA2814023C (en) 2010-10-08 2018-01-16 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
US9347950B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
AU2011325871B2 (en) 2010-11-05 2016-02-04 Medvet Science Pty Ltd Markers of endothelial progenitor cells and uses thereof
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640367A2 (de) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012083370A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
PL2663638T3 (pl) * 2011-01-12 2020-02-28 Oligogen Inc. Sposób hodowli w celu uzyskania i utrzymania czystej lub wzbogaconej populacji ssaczych nerwowych komórek macierzystych i/lub nerwowych komórek progenitorowych, które są podatne na różnicowanie w komórki linii oligodendrocytarnej in vitro
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
GB201101794D0 (en) 2011-02-02 2011-03-16 Fermentas Uab Protein production
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2828347A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
SG10201606950RA (en) 2011-03-31 2016-10-28 Genentech Inc Methods of administering beta7 integrin antagonists
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MY169935A (en) 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
MX359384B (es) 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9023995B2 (en) 2011-11-16 2015-05-05 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
CA2857168C (en) 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
KR20210025692A (ko) 2011-12-22 2021-03-09 제넨테크, 인크. 이온 교환 막 크로마토그래피
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
AU2013208003B2 (en) 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
AU2013222188A1 (en) 2012-02-22 2014-09-11 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
DK2841087T3 (da) 2012-04-27 2017-11-20 Us Health Vaskulær endothel-vækstfaktor-antagonister og fremgangsmåder til anvendelse deraf
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
WO2013177118A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of non-human antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2888238A4 (de) 2012-08-21 2016-01-27 Academia Sinica Benzocyclooctynverbindungen und verwendungen davon
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására
MX370416B (es) 2013-03-13 2019-12-10 Genentech Inc Formulaciones con oxidacion reducida.
JP6389236B2 (ja) 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド 酸化還元製剤
EP2968587A2 (de) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014158231A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
ES2665596T3 (es) 2013-03-15 2018-04-26 Glaxosmithkline Intellectual Property (No. 2) Limited Uso de compuestos intermedios de ácido tricarboxílico (ATC) para controlar la generación de amoníaco en cultivo celular
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
KR102235452B1 (ko) 2013-03-15 2021-04-02 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
RU2015144020A (ru) 2013-03-15 2017-04-21 Дженентек, Инк. Среды для культивирования клеток и способы получения антител
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
RU2015145610A (ru) 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
JP6682429B2 (ja) * 2013-06-11 2020-04-15 エンカルディア・ベー・フェー 多能性哺乳動物幹細胞に由来する心筋細胞を成熟させるための培地組成物
WO2014207534A2 (en) 2013-06-25 2014-12-31 Sépia Pesquisa E Desenvolvimento Bradykinin receptor modulators and use thereof
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3022221B1 (de) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanisierte antikörper mit ultralangen komplementaritätsbestimmenden regionen
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
PL3036320T3 (pl) 2013-08-19 2021-11-02 Biogen Ma Inc. Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
BR112016006321B1 (pt) 2013-09-23 2022-11-16 Braskem S.A Enzima engenheirada tendo especificidade de substrato aceto acetil-coa e atividade aceto acetil-coa específica de hidrolase, micro-organismo modificado, e, processo de produção de um ou mais produtos a partir de uma fonte de carbono fermentável
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6534654B2 (ja) 2013-10-10 2019-06-26 ベス イスラエル デアコネス メディカル センター インコーポレイティッド Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
CN105722523B (zh) 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG11201604632PA (en) 2013-12-09 2016-07-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
KR20240017102A (ko) 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
BR112016013741A2 (pt) 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CN105873949A (zh) 2014-01-31 2016-08-17 勃林格殷格翰国际有限公司 新的抗baff抗体
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP3110446B1 (de) 2014-02-28 2021-12-01 Allakos Inc. Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3647322B1 (de) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilisierte fibronectinbasierte gerüstmoleküle
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
DK3122869T3 (da) 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
JP6655548B2 (ja) 2014-03-25 2020-02-26 ジェネンテック， インコーポレイテッド 細胞培養培地における使用のためのポロキサマーを調製する方法
CN113604543A (zh) 2014-03-27 2021-11-05 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
BR122021009041B1 (pt) 2014-05-06 2022-11-29 Genentech, Inc Métodos para a preparação de uma proteína heteromultimérica
EP3149037A4 (de) 2014-05-27 2018-01-10 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR20230033737A (ko) 2014-05-27 2023-03-08 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
EP3145951A1 (de) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Verfahren zur reinigung von antikörpern
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
DK3172233T3 (da) 2014-07-22 2019-11-11 Sutro Biopharma Inc Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
EP3194435A1 (de) 2014-09-15 2017-07-26 Amgen Inc. Bispezifische anti-cgrp-rezeptor/pac1-rezeptor-antigenbindende proteine und verwendungen davon
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
JP6749898B2 (ja) 2014-10-15 2020-09-02 アムジエン・インコーポレーテツド 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP6788586B2 (ja) 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Ｈｎｌを用いる診断方法
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CA2972731A1 (en) 2015-01-24 2016-07-28 Chi-Huey Wong Cancer markers and methods of use thereof
CN114702581A (zh) 2015-01-30 2022-07-05 台湾地区“中央研究院” 增进抗体功效的通用糖型组合物及方法
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
EA201791734A1 (ru) 2015-02-04 2018-01-31 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения воспалительных заболеваний
AR103782A1 (es) 2015-02-26 2017-05-31 Genentech Inc ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
WO2016156537A1 (en) 2015-03-31 2016-10-06 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JP7019423B2 (ja) 2015-05-06 2022-02-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2016197491A1 (en) 2015-06-12 2016-12-15 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences A three-dimensional tissue scaffold with stem cell attracting element and use thereof
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
WO2017020001A2 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
SG10201914109VA (en) 2015-08-11 2020-02-27 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
AU2016307943A1 (en) 2015-08-14 2018-02-15 Allergan, Inc. Heavy chain only antibodies to PDGF
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3699269A1 (de) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression von fc-haltigen proteinen
EP3708580B1 (de) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Schnell ablaufende serumalbuminbindende fibronektin-typ-iii-domänen
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
AU2016381694A1 (en) 2015-12-30 2018-07-05 Genentech, Inc. Use of tryptophan derivatives for protein formulations
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
EP3407917A1 (de) 2016-01-27 2018-12-05 Sutro Biopharma, Inc. Anti-cd74-antikörperkonjukate, zusammensetzungen mit anti-cd74-antikörperkonjugaten und verfahren zur verwendung von anti-cd74-antikörperkonjugaten
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
EP3430054B1 (de) 2016-03-15 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und anti-gpc3-antikörpern
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
MX2018012410A (es) 2016-04-15 2019-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades inflamatorias.
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
MA45186A (fr) * 2016-06-03 2019-04-10 Janssen Biotech Inc Domaines de fibronectine de type iii se liant à l'albumine sérique
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
AR108800A1 (es) 2016-06-17 2018-09-26 Genentech Inc Purificación de anticuerpos multiespecíficos
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
BR112019001656A2 (pt) 2016-07-27 2019-05-28 Obi Pharma Inc composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
CN110062767B (zh) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
EP3497129A1 (de) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutische und diagnostische verfahren für krebs
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
EP3512541A1 (de) 2016-09-14 2019-07-24 Janssen Biotech, Inc. Chimäre antigenrezeptoren mit bcma-spezifischen fibronectin-typ-iii-domänen und verwendungen davon
EP3515950A4 (de) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. Neuartige anti-pcsk9-antikörper
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018071597A1 (en) 2016-10-12 2018-04-19 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
EP3848390A1 (de) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Verfahren zur behandlung von krankheiten
EP3532496A1 (de) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antikörper gegen ubiquitin c-terminale hydrolase l1 (uch-l1) und gliales fibrilläres saures protein (gfap) und verwandte verfahren
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018156777A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP4095161A1 (de) 2017-03-15 2022-11-30 Tsinghua University Neuartige anti-trkb-antikörper
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CA3058306A1 (en) * 2017-03-28 2018-10-04 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
EP4230649A3 (de) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
AU2018261887A1 (en) 2017-05-05 2019-12-05 Allakos Inc. Methods and compositions for treating allergic ocular diseases
WO2018217940A2 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
KR102623647B1 (ko) * 2017-06-27 2024-01-12 아지노모토 가부시키가이샤 리보플라빈 유도체 함유 배지
WO2019018402A2 (en) 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
SG11202000658PA (en) 2017-07-26 2020-02-27 Forty Seven Inc Anti-sirp-alpha antibodies and related methods
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
US10596270B2 (en) 2017-09-18 2020-03-24 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
KR20200110362A (ko) 2018-01-12 2020-09-23 암젠 인크 Pac1 항체 및 이의 용도
EP3740507A4 (de) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. Einzeldomänenantikörper und varianten davon gegen pd-1
BR112020014591A2 (pt) 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
KR20200133376A (ko) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. 신호-조절 단백질 알파에 대한 항체 및 사용 방법
US20210130483A1 (en) 2018-03-26 2021-05-06 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
WO2019185040A1 (en) 2018-03-30 2019-10-03 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against lag-3 and uses thereof
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
EP3774916A2 (de) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin-33-wirkstoffe und -zusammensetzungen und verfahren zur herstellung und verwendung davon
EP3788071A1 (de) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
JP2021523741A (ja) 2018-05-14 2021-09-09 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US20190367858A1 (en) 2018-06-01 2019-12-05 Lonza Ltd. Midscale Model For Organic Growth and Phasing
EP3810653A1 (de) 2018-06-23 2021-04-28 F. Hoffmann-La Roche AG Verfahren zur behandlung von lungenkrebs mit einem pd-1-achsen-bindenden antagonisten, einem platinmittel und einem topoisomerase-ii-inhibitor
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
KR20230065382A (ko) 2018-07-13 2023-05-11 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
KR102140531B1 (ko) 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
JP2021533149A (ja) 2018-08-08 2021-12-02 ジェネンテック， インコーポレイテッド タンパク質製剤のためのトリプトファン誘導体及びｌ−メチオニンの使用
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
US20210355215A1 (en) 2018-09-21 2021-11-18 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113365697A (zh) 2018-09-25 2021-09-07 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
EA202190609A1 (ru) 2018-09-27 2021-08-17 Тизона Терапьютикс Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
EP3870614A1 (de) 2018-10-23 2021-09-01 GlyCardial Diagnostics, S.L. Antikörper spezifisch für glykosyliertes apoj und verwendungen davon
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
JP2022514082A (ja) 2018-12-21 2022-02-09 ジェネンテック， インコーポレイテッド アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
EA202191784A1 (ru) 2018-12-26 2021-10-20 Сити Оф Хоуп Активируемые маскированные связывающие белки к ctla4
BR112021014481A2 (pt) 2019-01-23 2021-10-13 Genentech, Inc. Método para produzir um polipeptídeo multimérico, método para produzir um anticorpo biespecífico, pluralidade de polipeptídeos multiméricos, células hospedeiras eucarióticas recombinantes, método para identificar uma combinação de sequências e kit de polinucleotídeos
BR112021014582A2 (pt) 2019-02-15 2021-10-05 Just-Evotec Biologics, Inc. Sistemas, instalações e processos de biomanufatura automatizados
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3962946A1 (de) 2019-05-03 2022-03-09 Celgene Corporation Anti-bcma-antikörper-konjugat, zusammensetzungen damit und verfahren zu deren herstellung und verwendung
PE20220287A1 (es) 2019-05-09 2022-02-25 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
KR20220005568A (ko) 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2020238730A1 (zh) 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 新型cldn18.2结合分子
KR20220016139A (ko) 2019-05-30 2022-02-08 암젠 인크 항체 이량체화를 유도하기 위한 경첩 영역 조작
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
CN114746420A (zh) 2019-06-17 2022-07-12 苏特罗生物制药公司 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
CN114341187A (zh) 2019-07-12 2022-04-12 中外制药株式会社 抗突变型fgfr3抗体及其用途
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗ｍＧｌｕＲ５抗体及びその使用
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
EP4054590A1 (de) 2019-11-04 2022-09-14 Amgen Inc. Verfahren zur behandlung von leukämie
MX2022005566A (es) 2019-11-08 2022-07-19 Amgen Inc Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
EP4061838A1 (de) 2019-11-19 2022-09-28 Amgen Inc. Neues multispezifisches antikörperformat
CA3167733A1 (en) * 2020-01-14 2021-07-22 Ajinomoto Co., Inc. High-density cell culture method
CN115427447A (zh) 2020-01-17 2022-12-02 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
CN115916988A (zh) 2020-02-21 2023-04-04 布拉斯科公司 在酵母中生产乙醇和一种或多种副产物
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
KR20220159426A (ko) 2020-03-26 2022-12-02 제넨테크, 인크. 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
WO2021211493A1 (en) 2020-04-15 2021-10-21 Genentech, Inc. Copper loss mitigation
IL296664A (en) 2020-04-24 2022-11-01 Hoffmann La Roche Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
IL298431A (en) 2020-05-26 2023-01-01 Boehringer Ingelheim Int Anti-pd-1 antibodies
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
EP4172192A1 (de) 2020-06-24 2023-05-03 Genentech, Inc. Apoptoseresistente zelllinien
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
KR20230056766A (ko) 2020-08-28 2023-04-27 제넨테크, 인크. 숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
CN112538458A (zh) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) 用于重编程细胞的方法
US20220281914A1 (en) 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
TW202237657A (zh) 2021-01-29 2022-10-01 美商默沙東藥廠 計畫性死亡受體1(pd-1)抗體之組合物及獲得該組合物之方法
WO2022170008A2 (en) 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
CA3211581A1 (en) 2021-03-10 2022-09-15 Ellen WU Immunomodulatory molecules and uses thereof
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
CA3216559A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
CR20230531A (es) 2021-04-23 2024-01-08 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
CN117321086A (zh) 2021-04-26 2023-12-29 轩竹生物科技股份有限公司 一种双特异抗体偶联物
AR125490A1 (es) 2021-04-30 2023-07-19 Celgene Corp Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
EP4340876A1 (de) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
WO2023287707A1 (en) 2021-07-15 2023-01-19 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists
WO2023102077A1 (en) 2021-12-01 2023-06-08 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
US20230257455A1 (en) 2021-12-22 2023-08-17 Cdr-Life Ag Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing
WO2023172491A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods
WO2023172903A1 (en) 2022-03-08 2023-09-14 Amgen Inc. Modular vector (modvec) system: a platform for construction of next generation expression vectors
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024092064A1 (en) 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57186491A (en) * 1981-05-07 1982-11-16 Ajinomoto Co Inc Cultivation of fibroblast using fibronectin
JPS5823784A (ja) * 1981-08-04 1983-02-12 Ajinomoto Co Inc 哺乳動物細胞用培地
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8516415D0 (en) * 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
FR2600076A1 (fr) * 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
CS262822B1 (en) * 1986-10-03 1989-04-14 Kovar Jan Synthetic medium for the cultivation of myelomic cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10120835A1 (de) * 2001-04-27 2002-11-07 Sifin Inst Fuer Immunpraeparat Verfahren zur Herstellung von monoklonalen Antikörpern
DE10120835C2 (de) * 2001-04-27 2003-04-10 Sifin Inst Fuer Immunpraeparat Verfahren zur Herstellung von monoklonalen Antikörpern

Also Published As

Publication number Publication date
WO1990003430A1 (en) 1990-04-05
AU632065B2 (en) 1992-12-17
DE68925971D1 (de) 1996-04-18
ATE135397T1 (de) 1996-03-15
AU4310189A (en) 1990-04-18
JP2783294B2 (ja) 1998-08-06
JPH04501660A (ja) 1992-03-26
EP0435911B1 (de) 1996-03-13
EP0435911A1 (de) 1991-07-10

Similar Documents

Publication Publication Date Title
DE68925971T2 (de) Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5945337A (en) Method for culturing CD34+ cells in a serum-free medium
LV11721A (lv) Tabakas produkti vai tiem lidzigi dabasvielas saturosi produkti ar antioksidantu ipasibam un so produktu iegusanas panemiens
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
NZ210300A (en) Preparation of hyaluronic acid from bacterial culture
DE3869054D1 (de) Polypeptid-wachstumsfaktor aus milch.
CN105524882B (zh) 用于免疫杀伤细胞体外扩增的血清替代物组合
ES2139599T3 (es) Aditivo rico en elementos traza, metodo para prepararlo, preparacion en la que esta incluido el aditivo, y su uso.
Salem et al. Human AML colony growth in serum-free culture
JPS57170186A (en) Perfectly synthetic cell culture medium
DE3671040D1 (de) Verwendung von glutamin in form seiner di- und tripeptide im naehrmedium fuer zellkulturen.
AU610843B2 (en) Serum-free medium for the proliferation of lymphokine-activated killer cells
Tisdale Changes in tRNA methyltransferase activity and cellular S-adenosylmethionine content following methionine deprivation
Litchfield et al. Regulation of proteolytic enzyme production by Aeromonas proteolytica. II. Extracellular aminopeptidase
PT89289A (pt) Processo para a preparacao de uma composicao de protoplastos estabilizados
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
DE69110906T2 (de) Verwendung von Wirtszellphospholipiden zur Hemmung bakterieller Besiedlung.
ES2100199T3 (es) Suplemento de medio de cultivo para organismos estrictos.
Gysin et al. Regulation of the synthesis of S-100 protein in rat glial cells.
MD169C2 (ro) Tulpina algei Spirulina platensis (Nordst.) Geitl. CALU - producător de biomasă
Gruber et al. Cell and tissue culture media: history and terminology
Pirt et al. Environmental influences on growth of L and ERK mammalian cells in shake-flask cultures
ES8503480A1 (es) Un procedimiento para convertir un permeado de lactosa de suero lacteo en productos comercialmente utiles
Rastogi et al. Role of riboflavin and certain amino acids in the excystment of Schizopyrenus russelli
MD389G2 (ro) Mediu de cultură pentru Propionibacterium freudenreichii s.s. chermanii

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8339 Ceased/non-payment of the annual fee